The ESCMID Study Group for Infections in Compromised Hosts (ESGICH) helps push research and discussions around the topic of infections in immunocompromised hosts. Despite significant advances in science, medicine, and technique that have improved outcomes of immunocompromised patients – including those who received cellular therapeutics, solid organ transplantation and those with autoimmune conditions – the threat of opportunistic bacterial, fungal, and viral infections remains high. These infections are often difficult to diagnose and treat, with high rates of mortality and morbidity. The epidemiology of infections in these patients is constantly evolving, as are the optimal approached for prevention and treatment of these opportunistic infections. This is why their objectives are to:
Best Trainee Abstracts in Immunocompromised Hosts for ESCMID Global 2025
It is the second year that we will provide awards for fellows with an accepted abstract focused on infections in immunocompromised hosts to attend ESCMID Global 2025.
The abstract acceptance letter, a pdf of the abstract, proof of fellowship, and confirmation of ESCMID & ESGICH membership in current good standing is required. The amount is 500 Euro, four (4) awards are planned.
Deadline is February 28th, 12:00 AM CET.
The winners will be notified after week 11 (starting March 10th)
Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges.
Giannella M, Lanternier F, Dellière S, Groll AH, Mueller NJ, Alastruey-Izquierdo A, Slavin MA; ECCMID study groups on Invasive Fungal Infection and Infection in Immunocompromised Hosts. Clin Microbiol Infect. 2024 Aug 12:S1198-743X(24)00386-0
Solid organ transplantation in SARS-CoV-2 positive recipients: a web-survey among ESGICH members.
Lombardi A, Grossi P, ESCMID Study Group for Infection in Compromised Hosts (ESGICH). Clin Microbiol Infect, Volume 30, Issue 5, 684 – 687
Current management of SARS-CoV-2 infection in solid organ transplant recipients: Experience derived from an ESGICH–ESOT survey.
Visentin A, Pickavance E, San-Juan R, Grossi PA, Manuel O, Aguado JM. Transpl Infect Dis. 2024; 26:e14252
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients
Teh BW, Mikulska M, Averbuch D, de la Camara R, Hirsch HH, Akova M, Ostrosky-Zeichner L, Baddley JW, Tan BH, Mularoni A, Subramanian AK, La Hoz RM, Marinelli T, Boan P, AguadoJM, Grossi PA, Maertens J, Mueller NJ, Slavin MA. Lancet Infect Dis. 2024;24(1):e59–e68.
Goals to score: The need for a minimum reporting dataset in studies of infection events in immunocompromised patients.
Teh BW, Mikulska M, Mueller NJ, Slavin MA. Transpl Infect Dis. 2024;26(1):e1415.
If you have questions or comments for our study group, we warmly invite you to contact us!